Related Experiment Video

Updated: May 1, 2026

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria
10:27

Methods to Increase the Sensitivity of High Resolution Melting Single Nucleotide Polymorphism Genotyping in Malaria

Published on: November 10, 2015

12.2K

Genotyping single-nucleotide polymorphisms of human genes involved in organophosphate detoxification by

Ivan Kurdyukov1, Gennady Rodionov, Andrey Radilov

  • 1Research Institute of Hygiene, Occupational Pathology and Human Ecology (RIHOPHE), Russian Federal Medical Biological Agency, g/p Kuzmolovsky, St. Petersburg, Russia, 188663, splachnum@yandex.ru.

Analytical and Bioanalytical Chemistry
|April 8, 2014
PubMed

Insights

Paraoxonase-1 (PON1) and butyrylcholinesterase (BCHE) enzyme variants influence organophosphate toxicity sensitivity. High-resolution melting (HRM) effectively genotypes key single-nucleotide polymorphisms (SNPs) in PON1 and BCHE, aiding toxicity assessment.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacogenetics
  • Toxicology

Background:

  • Paraoxonase-1 (PON1) and butyrylcholinesterase (BCHE) are crucial endogenous bioscavengers protecting against organophosphate toxicity.
  • Genetic variations in PON1 (rs854560, rs662) and BCHE (rs1803274) significantly impact enzyme activity, substrate specificity, and individual susceptibility to organophosphates.
  • The atypical BCHE variant (rs1799807) exhibits reduced affinity for cholinesterase inhibitors, further modulating toxicity.

Purpose of the Study:

  • To evaluate the efficacy of high-resolution melting (HRM) analysis for genotyping key single-nucleotide polymorphisms (SNPs) associated with PON1 and BCHE.
  • To establish a reliable method for discriminating genotypes at rs854560, rs662, and rs1803274 for assessing organophosphate sensitivity.

Main Methods:

  • High-resolution melting (HRM) analysis was employed for genotyping.
  • Genotyping of rs662 and rs1803274 leverages nucleotide substitutions (A>G/G>A) that alter PCR product hydrogen bonds and melting temperature (Tm).
  • For rs854560, a modified HRM approach involving the addition of LL homozygote DNA before PCR was used to differentiate genotypes based on heteroduplex formation and melt curves.

Main Results:

  • HRM analysis successfully genotyped rs662 and rs1803274 SNPs, with nucleotide substitutions impacting Tm.
  • A specific HRM strategy enabled discrimination of the three genotypes for rs854560, overcoming challenges posed by its nucleotide substitution (T>A).
  • The study confirms HRM's applicability for genotyping these critical PON1 and BCHE SNPs.

Conclusions:

  • High-resolution melting (HRM) is a validated and efficient technique for genotyping human rs854560, rs662, and rs1803274 SNPs.
  • Accurate genotyping of these SNPs facilitates the assessment of individual sensitivity to organophosphate toxicity.
  • This method supports pharmacogenetic studies and clinical applications related to organophosphate exposure.

More Related Videos

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

2.0K
Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis06:30

Rapid and Efficient Zebrafish Genotyping Using PCR with High-resolution Melt Analysis

Published on: February 5, 2014

21.8K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121